US20100316999A1 - Nucleic Acid Sequence Analysis - Google Patents

Nucleic Acid Sequence Analysis Download PDF

Info

Publication number
US20100316999A1
US20100316999A1 US12/651,824 US65182410A US2010316999A1 US 20100316999 A1 US20100316999 A1 US 20100316999A1 US 65182410 A US65182410 A US 65182410A US 2010316999 A1 US2010316999 A1 US 2010316999A1
Authority
US
United States
Prior art keywords
polymerase
blocking group
nucleotides
polynucleotide
target polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/651,824
Inventor
Daniel Henry Densham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
REJUVIGEN Ltd
Gen Probe Inc
Cytyc Corp
Third Wave Technologies Inc
Hologic Inc
Suros Surgical Systems Inc
Biolucent LLC
Cytyc Surgical Products LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20100316999(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9715942.0A external-priority patent/GB9715942D0/en
Priority claimed from GBGB9727103.5A external-priority patent/GB9727103D0/en
Application filed by Individual filed Critical Individual
Priority to US12/651,824 priority Critical patent/US20100316999A1/en
Assigned to MOBIOUS BIOSYSTEMS LIMITED reassignment MOBIOUS BIOSYSTEMS LIMITED CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: REJUVIGEN LIMITED
Assigned to GEN-PROBE INCORPORATED reassignment GEN-PROBE INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MOBIOUS BIO SYSTEMS LIMITED
Assigned to REJUVIGEN LIMITED reassignment REJUVIGEN LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MEDICAL BIOSYSTEMS LIMITED
Publication of US20100316999A1 publication Critical patent/US20100316999A1/en
Assigned to GOLDMAN SACHS BANK USA reassignment GOLDMAN SACHS BANK USA SECURITY AGREEMENT Assignors: BIOLUCENT, LLC, CYTYC CORPORATION, CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP, GEN-PROBE INCORPORATED, HOLOGIC, INC., SUROS SURGICAL SYSTEMS, INC., THIRD WAVE TECHNOLOGIES, INC.
Assigned to GEN-PROBE INCORPORATED, CYTYC CORPORATION, HOLOGIC, INC., THIRD WAVE TECHNOLOGIES, INC., BIOLUCENT, LLC, CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP, SUROS SURGICAL SYSTEMS, INC. reassignment GEN-PROBE INCORPORATED SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Assignors: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Assigned to BANK OF AMERICA, N.A., AS COLLATERAL AGENT reassignment BANK OF AMERICA, N.A., AS COLLATERAL AGENT SECURITY AGREEMENT Assignors: BIOLUCENT, LLC, CYTYC CORPORATION, CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP, DIRECT RADIOGRAPHY CORP., GEN-PROBE INCORPORATED, GEN-PROBE PRODESSE, INC., HOLOGIC, INC., SUROS SURGICAL SYSTEMS, INC., THIRD WAVE TECHNOLOGIES, INC.
Assigned to GEN-PROBE INCORPORATED, CYTYC CORPORATION, HOLOGIC, INC., THIRD WAVE TECHNOLOGIES, INC., SUROS SURGICAL SYSTEMS, INC., BIOLUCENT, LLC, CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP reassignment GEN-PROBE INCORPORATED CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Assignors: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Assigned to GOLDMAN SACHS BANK USA reassignment GOLDMAN SACHS BANK USA CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Assignors: BIOLUCENT, LLC, CYTYC CORPORATION, CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP, GEN-PROBE INCORPORATED, HOLOGIC, INC., SUROS SURGICAL SYSTEMS, INC., THIRD WAVE TECHNOLOGIES, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6816Hybridisation assays characterised by the detection means
    • C12Q1/6825Nucleic acid detection involving sensors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing

Definitions

  • This invention relates to a method for determining the sequence of a polynucleotide.
  • the principal method in general use for large-scale DNA sequencing is the chain termination method. This method was first developed by Sanger and Coulson (Sanger et al. Proc. Natl. Acad. Sci. USA 1977; 74: 5463-5467), and relies on the use of dideoxy derivatives of the four nucleoside triphosphates which are incorporated into the nascent polynucleotide chain in a polymerase reaction. Upon incorporation, the dideoxy derivatives terminate the polymerase reaction and the products are then separated by gel electrophoresis and analysed to reveal the position at which the particular dideoxy derivative was incorporated into the chain.
  • EP-A-0471732 uses spectroscopic means to detect the incorporation of a nucleotide into a nascent polynucleotide strand complementary to a target.
  • the method relies on an immobilised complex of template and primer, which is exposed to a flow containing only one of the different nucleotides.
  • Spectroscopic techniques are then used to measure a time-dependent signal arising from the polymerase catalysed growth of the template copy.
  • the spectroscopic techniques described are surface plasmon resonance (SPR) spectroscopy, which measures changes in an analyte within an evanescent wave field, and fluorescence measuring techniques.
  • SPR surface plasmon resonance
  • the present invention is based on the realisation that the measurement of electromagnetic or other radiation can be used to detect a conformational and/or mass change in a polymerase enzyme which occurs when a nucleotide is incorporated into a nascent polynucleotide strand.
  • a method for sequencing a polynucleotide comprises the steps of:
  • the radiation may be applied to a sample using a number of techniques, including surface-sensitive detection techniques, where a change in the optical response at a solid optical surface is used to indicate a binding interaction at the surface.
  • the technique used is evanescent wave spectroscopy, in particular surface plasmon resonance (SPR) spectroscopy.
  • the nucleotides used in the method include a blocking group at the 3′ position, and optionally at the 5′ position, which prevents incorporation of the nucleotides into the polynucleotide strand.
  • the blocking groups may be selectively removed to allow incorporation to occur.
  • the selective removal of the blocking groups is carried out in a way that ensures the detection of each incorporated nucleotide. The method may therefore proceed on a “real-time” basis, to achieve a high rate of sequence analysis.
  • FIG. 1 is a schematic illustration of polynucleotide sequence analysis using SPR spectroscopy.
  • FIG. 2 illustrates the different response signals detected for the polymerisation of each of the different nucleotides.
  • FIG. 3 illustrates the synthesis procedure for the double blocked nucleotides.
  • the present method for sequencing a polynucleotide involves the analysis of the kinetic interaction between a polymerase enzyme, a target polynucleotide and a complementary nucleotide. Measurement of the kinetic interaction is carried out by monitoring the changes in or absorption of electromagnetic or other radiation that occurs if the reaction proceeds.
  • polynucleotide as used herein is to be interpreted broadly, and includes DNA and RNA, including modified DNA and RNA, as well as other hybridising nucleic acid-like molecules, e.g. peptide nucleic acid (PITA).
  • PITA peptide nucleic acid
  • the method is carried out by applying electromagnetic radiation, by using the techniques of surface plasmon resonance or nuclear magnetic resonance.
  • techniques which measure changes in radiation may be considered, for example spectroscopy by total internal reflectance fluorescence (TIRF), attenuated total reflection (ATR), frustrated total reflection (FTR), Brewster angle reflectometry, scattered total internal reflection (STIR) or evanescent wave ellipsometry.
  • Techniques other than those requiring electromagnetic radiation are also envisaged, in particular photochemical techniques such as chemiluminescence, and gravimetric techniques including resonant systems such as surface acoustic wave (SAW) techniques and quartz crystal microbalance (QCM) techniques.
  • photochemical techniques such as chemiluminescence
  • gravimetric techniques including resonant systems such as surface acoustic wave (SAW) techniques and quartz crystal microbalance (QCM) techniques.
  • SAW surface acoustic wave
  • QCM quartz crystal microbalance
  • SPR Surface plasmon resonance
  • Suitable sensor chips are known in the art. Typically, they comprise an optically transparent material, e.g. glass, and a thin reflective film, e.g. silver or gold.
  • a thin reflective film e.g. silver or gold.
  • Nuclear magnetic resonance (NMR) spectroscopy is another preferred method, and measures the magnetic properties of compounds. Nuclei of compounds are energetically orientated by a combination of applied magnetic field and radio-frequency radiation. When the energy exerted on a nucleus equals the energy difference between spin states (the difference between orientation parallel or anti-parallel to the direction of the applied fields), a condition known as resonance is achieved. The absorption and subsequent emission of energy associated with the change from one spin state to the other, is detected by a radio-frequency receiver.
  • An important aspect of the method of the present invention is the use of a polymerase enzyme immobilised onto a solid support. Immobilisation of the polymerase offers several important advantages for the success of this method. Firstly, the problem of random “noise” associated with measuring energy absorption in soluble molecules is reduced considerably. Secondly, the problem of noise from the interaction of any substrate (e.g. nucleotides) not directly involved with the polymerase is reduced, as the polymerase can be maintained within a specifically defined area relative to the field of measurement. This is particularly relevant if the technique used to measure the changes in radiation requires the measurement of fluorescence, as in TIRF, where background fluorescence increases as the nascent chain grows.
  • any substrate e.g. nucleotides
  • the polymerase reactions are maintained within the evanescent wave field and so accurate measurements can be made irrespective of the size of the polynucleotide.
  • the target polynucleotide nor the oligonucleotide primer is irreversibly attached to the solid surface, it is relatively simple to regenerate the surface, to allow further sequencing reactions to take place using the same immobilised polymerase.
  • Immobilisation may be carried out using standard procedures known in the art.
  • immobilisation using standard amine coupling procedures may be used, with attachment of ligand-associated amines to, say, a dextran or N-hydroxysuccinimide ester-activated surface.
  • the polymerase is immobilised onto a SPR sensor chip surface which maintains the polymerase in close proximity to the sensor surface where changes in the refractive index may be measured. Examples of procedures used to immobilise biomolecules to optical sensors are disclosed in EP-A-0589867, and Löfas et al., Biosens. Bioelectron. (1995) 10:813-822.
  • the polymerase used in the invention may be of any known type.
  • the polymerase may be any DNA-dependent DNA polymerase.
  • the polymerase may be a RNA-dependent DNA polymerase, i.e. reverse transcriptase, or a RNA-dependent RNA polymerase, i.e. RNA replicase.
  • the polymerase is Taq polymerase.
  • the polymerase is either E. coli polymerase III holoenzyme (McHenry, Ann. Rev. Biochem.
  • T7 polymerase (Schwager et al., Methods in Molecular and Cellular Biology (1989/90) Vol. 1 (4):155-159, or Bacteriophage T7 gene 5 polymerase complexed with E. coli Thioredoxin (Tabor et al., J. Biol. Chem. (1987); 262:1612-1623).
  • Each of these polymerase enzymes allows a binding with the target polynucleotide to occur with high fidelity and therefore maintains a polymerase-polynucleotide complex, even when polymerisation is not actively taking place.
  • the polymerase III holoenzyme is composed of three subassemblies that function to create the processive enzyme: (I) the polymerase core, including the polymerase subunit ⁇ ; (II) ⁇ -dimer subunit which acts as a bracelet-like structure around DNA; and (III) a subassembly of two subunits, ⁇ and ⁇ , used to bind and hydrolyse ATP to form the ⁇ -dimer around the DNA.
  • the target polynucleotide may be brought into contact with an appropriate primer in hybridising/polymerisation buffer.
  • the buffer will be at a sufficiently high temperature to disrupt (or melt) any secondary structures that exist on the target polynucleotide.
  • the primer will anneal to its complement on the target.
  • This sample may then be brought into contact with the immobilised polymerase, to form the target polynucleotide/polymerase complex.
  • the addition of the nucleotides is controlled so that the different nucleotides are added sequentially to the polymerase/target complex.
  • dGTP may be added and allowed to flow over the polymerase/polynucleotide complex; any incorporation is then detected. Unbound dGTP flows out of the reaction site and a further nucleotide is introduced. In this manner, the detection of a kinetic interaction can be correlated to the particular nucleotide present at that time and the polynucleotide sequence can therefore be determined.
  • the method may also be carried out with all the different nucleotides present.
  • the nucleotides may incorporate a blocking group at least at the 3′ position, but preferably at the 3′ and 5′ positions.
  • the blocking groups may be light-sensitive and can be removed by applying light of a defined wave length, to release the active molecule. If the nucleotides incorporate blocking groups at both the 3′ and 5′ positions, the blocking groups should be capable of being distinguished on the basis of their spectral absorbency, i.e. it should be possible to remove selectively one of the blocking groups by applying a specific wavelength of light which does not remove the other blocking group. It is also desirable that the blocking group at the 3′ position requires the light to be applied for a longer duration than that required to remove the blocking group at the 5′ position. This allows the blocking groups to be distinguished by both spectral and temporal means.
  • the light-sensitive blocking groups undergo photolysis at wavelengths in the range from 200 nm to 450 nm.
  • the blocking groups will typically be derived from a compound of the formula R 1 —[O—CO—]X wherein R′ is a photolabile group and X is a leaving group.
  • R 1 is o-nitrobenzyl.
  • Particularly preferred blocking groups include the o-nitrobenzyl protecting groups described in WO-A-92/10092 and WO-A-97/39151.
  • NVOC nitroveratryloxycarbonyl
  • NPOC nitropiperonyloxycarbonyl
  • MeNVOC ⁇ -methyl-nitroveratryloxycarbonyl
  • MeNPOC ⁇ -methyl-nitropiperonyloxycarbonyl
  • PYMOC 1-pyrenylmethyloxycarbonyl
  • a suitable 3′ blocking group is a (4,5-dimethoxy-2-nitrobenzyl)oxycarbonyl group which can be formed by reaction of the nucleotide with a compound of formula (I):
  • R is any suitable esterifying group, e.g. methyl.
  • This blocking group can be selectively removed by a pulse of light with a wavelength of 360 nm.
  • a suitable blocking group at the 5′ position is 1-(2-nitrophenyl)ethyl group (II):
  • R is any suitable functional group, e.g. halogen.
  • This blocking group may be selectively removed at a wavelength of 260 nm.
  • double-blocked nucleotides are injected over the primed target polynucleotide (held in association with a high fidelity polymerase complex), and monochromatic light is focussed upstream of the polymerase at a wavelength sufficient to release the blocking group from the terminal phosphate of each nucleotide.
  • the nucleotides are then able to flow over the bound polymerase, and incorporation into the nascent polynucleotide strand can occur.
  • the blocking group at the 3′ position remains bound, only one nucleotide is incorporated. A measurement of the kinetic interaction will therefore provide information as to the particular nucleotide incorporated into the nascent chain.
  • the polymerase used may be a high fidelity polymerase which does not dissociate readily from the target when the reaction stops. Alternatively, a competitive inhibitor may be used to prevent the polymerase dissociating from the target.
  • a pulse of monochromatic light is focused on the blocking group within the polymerase catalytic site, to remove the blocking group at the 3′ position.
  • the monochromatic light may be pulsed for a longer duration than that required for removal at the 5′ position, and so only the blocking group associated with the nucleotide in the polymerase complex will undergo removal. This reduces the likelihood of the addition of nucleotides not associated with the polymerase complex.
  • the polymerase reaction is allowed to continue as further nucleotides arrive at the polymerase reaction site. Uncontrolled polymerisation is prevented by alternating the pulses of light required to remove the blocking groups.
  • the procedure may also be carried out using nucleotides having a blocking group at the 3′ position only.
  • a competitive inhibitor of the polymerase which will reduce the probability of a nucleotide lacking a blocking group at the 3′ position being incorporated into the nascent chain.
  • a suitable competitive inhibitor of polymerase is carbonyldiphosphonate (COMDP).
  • the following analysis was carried out on a modified BIAcore 2000 system (BIAcore AB, UPPSALA, Sweden) with a sensor chip CM5 (Research grade, BIAcore AB) as the optical sensor surface.
  • the instrument was provided with an integrated ⁇ m-fluidic cartridge (IFC) which allows analysis in four cells by a single sample injection.
  • IFC integrated ⁇ m-fluidic cartridge
  • E. Coli polymerase III holoenzyme was prepared according to (Millard et al., Methods Enzymol. (1995); 262:22) using hydrophobic interaction chromatography on valyl-Sepharose, to purify the holoenzyme at high salt concentrations. After purification, the hollow enzyme was concentrated using the ion-filtration technique described by Kirkegaard et al, Anal. Biochem. (1972); 50:122.
  • the polymerase III Subassembly core 160 ⁇ l, 500 U was mixed with 10 mM sodium acetate (100 ⁇ l, pH 5) and injected across the activated surface. Finally, residual N-hydroxysuccinimide esters on the sensor chip surface were reacted with ethanolamine (35 ⁇ l, 1 M in water, pH 8.5), and non-bound polymerase was washed from the surface. The immobilisation procedure was performed with a continuous flow of Hepes buffer (5 ⁇ l/min) at a temperature of 25° C.
  • oligonucleotides Two oligonucleotides were synthesised using standard phosphoramidite chemistry.
  • the oligonucleotide defined as SEQ ID No. 1 was used as the target polynucleotide, and the oligonucleotide defined as SEQ ID No. 2 was used as the primer.
  • the two oligonucleotides were reacted under hybridising conditions to form the target-primer complex.
  • the primed DNA was then suspended in buffer (20 mM Tris-HCl, pH 7.5, 8 mM MgCl 2 , 4% (v/v) glycerol, 5 mM dithiothreitol (DDT), 40 ⁇ g bovine serum albumin) containing 21 ⁇ g ssDNA binding-protein and the DNA pol III sub-assembly, required to form the bracelet-like structure (1.6 pmol ⁇ -dimer and 195 fmol ⁇ subunits).
  • 0.5 mM ATP was present together with 60 ⁇ M carbonyldiphosphonate (COMDP).
  • the ⁇ subunit acts as a molecular matchmaker, hydrolysing ATP to place the ⁇ -dimer subunits onto the DNA to form the polymerase sub-assembly (Studwell et al, UCLA Symp. Mol. Cell. Biol. New Ser. 1990; 127: 153).
  • the primed DNA/sub-assembly complex was then injected over the polymerase III on the sensor chip surface at a flow-rate of 5 ⁇ m/min, and allowed to bind to the polymerase via the action of the ⁇ subunits.
  • magnesium and ATP are needed for the Pol III to bind to the primed DNA.
  • magnesium also promotes removal of the primer by the proof-reading 3′-5′ exonuclease activity. This problem is circumvented by including the carbonyldiphosphonate, which is a competitive inhibitor of polymerase activity (a pol III lacking the exonuclease activity may be used to avoid this particular problem).
  • a continuous flow of 60 ⁇ M carbonyldiphosphonate was maintained over the chip surface, to prevent the exonuclease activity from removing the primer from the target DNA.
  • Each nucleotide (dCTP, dTTP, dGTP and dATP) contained a 1-(2-nitrophenyl)ethyl blocking group at the 5′ position, and a (4,5-dimethoxy-2-nitrobenzyl) oxycarbonyl blocking group at the 3′ position as shown in FIG. 3 .
  • the synthesis of the double blocked nucleotides was as follows:
  • Stage 2 —Addition of the 5′ 1-(2-nitrophenyl)ethyl group to the 3′ 4,5-dimethoxy-2-nitrobenzyl oxycarbonyl blocked dATP
  • the residual material which contained among other substances unreacted 4,5-dimethoxy-2-nitrobenzyl oxycarbonyl 5′ dATP and the desired double blocked dATP, was dissolved in a minimal amount of chloroform and separated by flash chromatography on a silica column 3 ⁇ 30 cm. Elution using 100% chloroform removed hydrophobic side products of 1-(2-nitrophenyl)diazoethane from the column. The product was dried on a rotary evaporator. Lyophilization gave 74 mg of the caged compound. The overall yield was 57%.
  • each nucleotide was present in the polymerisation buffer (1 mM Tris-HCl pH 8.8, 5 mM KCl, 0.15 mM MgCl 2 , 0.01% (w/v) gelatin).
  • FIG. 1 shows a SPR sensing system and fluidic cell ( 7 ), having a means for applying electromagnetic radiation ( 1 ) to a sensor chip ( 2 ) with an immobilised polymerase enzyme ( 3 ) at the sensor surface, an inlet ( 4 ) for introducing the different nucleotides into the cell and two focusing assemblies ( 5 ) and ( 6 ) for pulsing monochromatic light into the cell.
  • the different nucleotides are introduced into the fluidic cell ( 7 ) at a flow rate of 30 ⁇ l/min., at a temperature of 25° C. and a data collection rate of 10 Hz.
  • the focusing assembly ( 5 ) monochromatic light at a wavelength of 260 nm is pulsed to remove the blocking group at the 5′ position.
  • the nucleotides then flow over the sensor chip ( 2 ) and contact the target polynucleotide/polymerase complex ( 3 ) which is held in place by the ⁇ -dimer sub-assembly.
  • FIG. 2 shows the results from the sequencing experiment with each nucleotide incorporated into the nascent chain being detected.
  • the results show a sequence complementary to that of SEQ ID No. 1.

Abstract

The present invention relates to a method for determining the sequence of a polynucleotide, the method comprising the steps of: (i) reacting a target polynucleotide with a polymerase enzyme immobilised on a solid support, and the different nucleotides, under conditions sufficient for the polymerase reaction; and (ii) detecting the incorporation of a specific nucleotide complementary to the target polynucleotide, by measuring radiation.

Description

    FIELD OF THE INVENTION
  • This invention relates to a method for determining the sequence of a polynucleotide.
  • BACKGROUND OF THE INVENTION
  • The ability to determine the sequence of a polynucleotide is of great scientific importance. For example, the Human Genome Project is an ambitious international effort to map and sequence the three billion basis of DNA encoded in the human genome. When complete, the resulting sequence database will be a tool of unparalleled power for biomedical research. The major obstacle to the successful completion of this project concerns the technology used in the sequencing process.
  • The principal method in general use for large-scale DNA sequencing is the chain termination method. This method was first developed by Sanger and Coulson (Sanger et al. Proc. Natl. Acad. Sci. USA 1977; 74: 5463-5467), and relies on the use of dideoxy derivatives of the four nucleoside triphosphates which are incorporated into the nascent polynucleotide chain in a polymerase reaction. Upon incorporation, the dideoxy derivatives terminate the polymerase reaction and the products are then separated by gel electrophoresis and analysed to reveal the position at which the particular dideoxy derivative was incorporated into the chain.
  • Although this method is widely used and produces reliable results, it is recognised that it is slow, labour-intensive and expensive.
  • An alternative sequencing method is proposed in EP-A-0471732, which uses spectroscopic means to detect the incorporation of a nucleotide into a nascent polynucleotide strand complementary to a target. The method relies on an immobilised complex of template and primer, which is exposed to a flow containing only one of the different nucleotides. Spectroscopic techniques are then used to measure a time-dependent signal arising from the polymerase catalysed growth of the template copy. The spectroscopic techniques described are surface plasmon resonance (SPR) spectroscopy, which measures changes in an analyte within an evanescent wave field, and fluorescence measuring techniques. However, limitations of this method are recognised; the most serious for the SPR technique being that, as the size of the copy strand grows, the absolute size of the signal also grows due to the movement of the strand out of the evanescent wave field, making it harder to detect increments. The fluorescence measuring techniques have the disadvantage of increasing background interference from the fluorophores incorporated on the growing nascent polynucleotide chain. As the chain grows, the background “noise” increases and the time required to detect each nucleotide incorporation needs to be increased. This severely restricts the use of the method for sequencing large polynucleotides.
  • There is therefore a need for an improved method for determining the sequence of polynucleotides which significantly increases the rate at which a polynucleotide is sequenced and which is preferably carried out by an automated process, reducing the complexity and cost associated with existing methods.
  • SUMMARY OF THE INVENTION
  • The present invention is based on the realisation that the measurement of electromagnetic or other radiation can be used to detect a conformational and/or mass change in a polymerase enzyme which occurs when a nucleotide is incorporated into a nascent polynucleotide strand.
  • According to the present invention, a method for sequencing a polynucleotide comprises the steps of:
  • (i) reacting a target polynucleotide with a polymerase enzyme immobilised on a solid support, and the different nucleotides, under conditions sufficient for the polymerase reaction; and
  • (ii) detecting the incorporation of a specific nucleotide complementary to the target polynucleotide, by measuring radiation.
  • The radiation may be applied to a sample using a number of techniques, including surface-sensitive detection techniques, where a change in the optical response at a solid optical surface is used to indicate a binding interaction at the surface. In a preferred embodiment of the invention, the technique used is evanescent wave spectroscopy, in particular surface plasmon resonance (SPR) spectroscopy.
  • In an embodiment of the invention, the nucleotides used in the method include a blocking group at the 3′ position, and optionally at the 5′ position, which prevents incorporation of the nucleotides into the polynucleotide strand. However, the blocking groups may be selectively removed to allow incorporation to occur. By using the blocked nucleotides, it is possible for the method to be carried out using all the nucleotides present in the reaction at any one time. The selective removal of the blocking groups is carried out in a way that ensures the detection of each incorporated nucleotide. The method may therefore proceed on a “real-time” basis, to achieve a high rate of sequence analysis.
  • DESCRIPTION OF THE DRAWINGS
  • The invention will be described by way of example only with reference to the following drawings, where:
  • FIG. 1 is a schematic illustration of polynucleotide sequence analysis using SPR spectroscopy; and
  • FIG. 2 illustrates the different response signals detected for the polymerisation of each of the different nucleotides.
  • FIG. 3 illustrates the synthesis procedure for the double blocked nucleotides.
  • DESCRIPTION OF THE INVENTION
  • The present method for sequencing a polynucleotide involves the analysis of the kinetic interaction between a polymerase enzyme, a target polynucleotide and a complementary nucleotide. Measurement of the kinetic interaction is carried out by monitoring the changes in or absorption of electromagnetic or other radiation that occurs if the reaction proceeds.
  • The term “polynucleotide” as used herein is to be interpreted broadly, and includes DNA and RNA, including modified DNA and RNA, as well as other hybridising nucleic acid-like molecules, e.g. peptide nucleic acid (PITA).
  • Typically, the method is carried out by applying electromagnetic radiation, by using the techniques of surface plasmon resonance or nuclear magnetic resonance. However, other techniques which measure changes in radiation may be considered, for example spectroscopy by total internal reflectance fluorescence (TIRF), attenuated total reflection (ATR), frustrated total reflection (FTR), Brewster angle reflectometry, scattered total internal reflection (STIR) or evanescent wave ellipsometry.
  • Techniques other than those requiring electromagnetic radiation are also envisaged, in particular photochemical techniques such as chemiluminescence, and gravimetric techniques including resonant systems such as surface acoustic wave (SAW) techniques and quartz crystal microbalance (QCM) techniques.
  • Surface plasmon resonance (SPR) spectroscopy is a preferred method, and measures the properties of a solution by detecting the differences in refractive index between the bulk phase of the solution and the evanescent wave region. Incident monochromatic light is reflected at a specific angle off a solid optical (sensor chip) surface on the opposite side to a sample under study. The light extends into the sample for a very short distance and is affected by an interaction at the surface.
  • Suitable sensor chips are known in the art. Typically, they comprise an optically transparent material, e.g. glass, and a thin reflective film, e.g. silver or gold. For a review of SPR spectroscopy see European Patent Publication No. 0648328 (the entire disclosure of which is incorporated herein by reference).
  • Nuclear magnetic resonance (NMR) spectroscopy is another preferred method, and measures the magnetic properties of compounds. Nuclei of compounds are energetically orientated by a combination of applied magnetic field and radio-frequency radiation. When the energy exerted on a nucleus equals the energy difference between spin states (the difference between orientation parallel or anti-parallel to the direction of the applied fields), a condition known as resonance is achieved. The absorption and subsequent emission of energy associated with the change from one spin state to the other, is detected by a radio-frequency receiver.
  • An important aspect of the method of the present invention is the use of a polymerase enzyme immobilised onto a solid support. Immobilisation of the polymerase offers several important advantages for the success of this method. Firstly, the problem of random “noise” associated with measuring energy absorption in soluble molecules is reduced considerably. Secondly, the problem of noise from the interaction of any substrate (e.g. nucleotides) not directly involved with the polymerase is reduced, as the polymerase can be maintained within a specifically defined area relative to the field of measurement. This is particularly relevant if the technique used to measure the changes in radiation requires the measurement of fluorescence, as in TIRF, where background fluorescence increases as the nascent chain grows. Also, if SPR spectroscopy is used, the polymerase reactions are maintained within the evanescent wave field and so accurate measurements can be made irrespective of the size of the polynucleotide. Finally, as neither the target polynucleotide nor the oligonucleotide primer is irreversibly attached to the solid surface, it is relatively simple to regenerate the surface, to allow further sequencing reactions to take place using the same immobilised polymerase.
  • Immobilisation may be carried out using standard procedures known in the art. In particular, immobilisation using standard amine coupling procedures may be used, with attachment of ligand-associated amines to, say, a dextran or N-hydroxysuccinimide ester-activated surface. In a preferred embodiment of the invention, the polymerase is immobilised onto a SPR sensor chip surface which maintains the polymerase in close proximity to the sensor surface where changes in the refractive index may be measured. Examples of procedures used to immobilise biomolecules to optical sensors are disclosed in EP-A-0589867, and Löfas et al., Biosens. Bioelectron. (1995) 10:813-822.
  • The polymerase used in the invention may be of any known type. For example, the polymerase may be any DNA-dependent DNA polymerase. If the target polynucleotide is a RNA molecule, then the polymerase may be a RNA-dependent DNA polymerase, i.e. reverse transcriptase, or a RNA-dependent RNA polymerase, i.e. RNA replicase. In a preferred embodiment of the invention, the polymerase is Taq polymerase. In a further preferred embodiment of the invention, the polymerase is either E. coli polymerase III holoenzyme (McHenry, Ann. Rev. Biochem. 1988; 57:519), T7 polymerase (Schwager et al., Methods in Molecular and Cellular Biology (1989/90) Vol. 1 (4):155-159, or Bacteriophage T7 gene 5 polymerase complexed with E. coli Thioredoxin (Tabor et al., J. Biol. Chem. (1987); 262:1612-1623). Each of these polymerase enzymes allows a binding with the target polynucleotide to occur with high fidelity and therefore maintains a polymerase-polynucleotide complex, even when polymerisation is not actively taking place.
  • The polymerase III holoenzyme is composed of three subassemblies that function to create the processive enzyme: (I) the polymerase core, including the polymerase subunit α; (II) β-dimer subunit which acts as a bracelet-like structure around DNA; and (III) a subassembly of two subunits, τ and γ, used to bind and hydrolyse ATP to form the β-dimer around the DNA.
  • As a first step in the sequencing process, the target polynucleotide may be brought into contact with an appropriate primer in hybridising/polymerisation buffer. Typically, the buffer will be at a sufficiently high temperature to disrupt (or melt) any secondary structures that exist on the target polynucleotide. On cooling, the primer will anneal to its complement on the target. This sample may then be brought into contact with the immobilised polymerase, to form the target polynucleotide/polymerase complex.
  • In one embodiment of the invention, the addition of the nucleotides is controlled so that the different nucleotides are added sequentially to the polymerase/target complex. For example, dGTP may be added and allowed to flow over the polymerase/polynucleotide complex; any incorporation is then detected. Unbound dGTP flows out of the reaction site and a further nucleotide is introduced. In this manner, the detection of a kinetic interaction can be correlated to the particular nucleotide present at that time and the polynucleotide sequence can therefore be determined.
  • The method may also be carried out with all the different nucleotides present. For this to be carried out successfully, it is necessary for the nucleotides to incorporate a blocking group at least at the 3′ position, but preferably at the 3′ and 5′ positions. The blocking groups may be light-sensitive and can be removed by applying light of a defined wave length, to release the active molecule. If the nucleotides incorporate blocking groups at both the 3′ and 5′ positions, the blocking groups should be capable of being distinguished on the basis of their spectral absorbency, i.e. it should be possible to remove selectively one of the blocking groups by applying a specific wavelength of light which does not remove the other blocking group. It is also desirable that the blocking group at the 3′ position requires the light to be applied for a longer duration than that required to remove the blocking group at the 5′ position. This allows the blocking groups to be distinguished by both spectral and temporal means.
  • Generally, the light-sensitive blocking groups undergo photolysis at wavelengths in the range from 200 nm to 450 nm. The blocking groups will typically be derived from a compound of the formula R1—[O—CO—]X wherein R′ is a photolabile group and X is a leaving group. For example, R1 is o-nitrobenzyl. Particularly preferred blocking groups include the o-nitrobenzyl protecting groups described in WO-A-92/10092 and WO-A-97/39151. These groups include nitroveratryloxycarbonyl (NVOC), nitropiperonyloxycarbonyl (NPOC), α-methyl-nitroveratryloxycarbonyl (MeNVOC), α-methyl-nitropiperonyloxycarbonyl (MeNPOC) and 1-pyrenylmethyloxycarbonyl (PYMOC).
  • A suitable 3′ blocking group is a (4,5-dimethoxy-2-nitrobenzyl)oxycarbonyl group which can be formed by reaction of the nucleotide with a compound of formula (I):
  • Figure US20100316999A1-20101216-C00001
  • wherein R is any suitable esterifying group, e.g. methyl. This blocking group can be selectively removed by a pulse of light with a wavelength of 360 nm.
  • A suitable blocking group at the 5′ position is 1-(2-nitrophenyl)ethyl group (II):
  • Figure US20100316999A1-20101216-C00002
  • wherein R is any suitable functional group, e.g. halogen. This blocking group may be selectively removed at a wavelength of 260 nm.
  • By way of example, double-blocked nucleotides are injected over the primed target polynucleotide (held in association with a high fidelity polymerase complex), and monochromatic light is focussed upstream of the polymerase at a wavelength sufficient to release the blocking group from the terminal phosphate of each nucleotide. The nucleotides are then able to flow over the bound polymerase, and incorporation into the nascent polynucleotide strand can occur. However, as the blocking group at the 3′ position remains bound, only one nucleotide is incorporated. A measurement of the kinetic interaction will therefore provide information as to the particular nucleotide incorporated into the nascent chain. The polymerase used may be a high fidelity polymerase which does not dissociate readily from the target when the reaction stops. Alternatively, a competitive inhibitor may be used to prevent the polymerase dissociating from the target.
  • After measuring the incorporated nucleotide, a pulse of monochromatic light is focused on the blocking group within the polymerase catalytic site, to remove the blocking group at the 3′ position. The monochromatic light may be pulsed for a longer duration than that required for removal at the 5′ position, and so only the blocking group associated with the nucleotide in the polymerase complex will undergo removal. This reduces the likelihood of the addition of nucleotides not associated with the polymerase complex.
  • Once the 3′ blocking group is released, the polymerase reaction is allowed to continue as further nucleotides arrive at the polymerase reaction site. Uncontrolled polymerisation is prevented by alternating the pulses of light required to remove the blocking groups.
  • While it is preferred to use the double-blocked nucleotides, as described above, the procedure may also be carried out using nucleotides having a blocking group at the 3′ position only. In this case, it is desirable to use a competitive inhibitor of the polymerase, which will reduce the probability of a nucleotide lacking a blocking group at the 3′ position being incorporated into the nascent chain. A suitable competitive inhibitor of polymerase is carbonyldiphosphonate (COMDP).
  • The following Example illustrates the invention with reference to the drawings.
  • Example
  • The following analysis was carried out on a modified BIAcore 2000 system (BIAcore AB, UPPSALA, Sweden) with a sensor chip CM5 (Research grade, BIAcore AB) as the optical sensor surface. The instrument was provided with an integrated μm-fluidic cartridge (IFC) which allows analysis in four cells by a single sample injection.
  • Preparation of Polymerase
  • E. Coli polymerase III holoenzyme was prepared according to (Millard et al., Methods Enzymol. (1995); 262:22) using hydrophobic interaction chromatography on valyl-Sepharose, to purify the holoenzyme at high salt concentrations. After purification, the hollow enzyme was concentrated using the ion-filtration technique described by Kirkegaard et al, Anal. Biochem. (1972); 50:122.
  • Immobilisation of the Polymerase
  • Immobilisation of the polymerase to the sensor chip surface was carried out according to (Jönsson et al., Biotechniques (1991); 11:620-627). Briefly, the sensor chip environment was equilibrated with Hepes buffer (10 mM Hepes, 150 mM NaCl, 0.05% surfactant P20 (BIAcore AB, Uppsala, Sweden), pH 7.4). Equal volumes of N-hydroxysuccinimide (0.1 M in water) and N-ethyl-n′-(dimethylaminopropyl) carbodiimide (EDC) (0.1 M in water) were mixed together and injected across the chip (CM5) surface, to activate the carboxymethylated dextran. The polymerase III Subassembly core (160 μl, 500 U) was mixed with 10 mM sodium acetate (100 μl, pH 5) and injected across the activated surface. Finally, residual N-hydroxysuccinimide esters on the sensor chip surface were reacted with ethanolamine (35 μl, 1 M in water, pH 8.5), and non-bound polymerase was washed from the surface. The immobilisation procedure was performed with a continuous flow of Hepes buffer (5 μl/min) at a temperature of 25° C.
  • Oligonucleotides
  • Two oligonucleotides were synthesised using standard phosphoramidite chemistry. The oligonucleotide defined as SEQ ID No. 1 was used as the target polynucleotide, and the oligonucleotide defined as SEQ ID No. 2 was used as the primer.
  • SEQ ID No. 1
    CAAGGAGAGGACGCTGTCTGTCGAAGGTAAGGAACGGACGAGAGAAGGGA
    GAG
    SEQ ID No. 2
    CTCTCCCTTCTCTCGTC
  • The two oligonucleotides were reacted under hybridising conditions to form the target-primer complex.
  • The primed DNA was then suspended in buffer (20 mM Tris-HCl, pH 7.5, 8 mM MgCl2, 4% (v/v) glycerol, 5 mM dithiothreitol (DDT), 40 μg bovine serum albumin) containing 21 μg ssDNA binding-protein and the DNA pol III sub-assembly, required to form the bracelet-like structure (1.6 pmol β-dimer and 195 fmol γ subunits). 0.5 mM ATP was present together with 60 μM carbonyldiphosphonate (COMDP). In this reaction, the γ subunit acts as a molecular matchmaker, hydrolysing ATP to place the β-dimer subunits onto the DNA to form the polymerase sub-assembly (Studwell et al, UCLA Symp. Mol. Cell. Biol. New Ser. 1990; 127: 153).
  • The primed DNA/sub-assembly complex was then injected over the polymerase III on the sensor chip surface at a flow-rate of 5 μm/min, and allowed to bind to the polymerase via the action of the γ subunits.
  • In this experiment, magnesium and ATP are needed for the Pol III to bind to the primed DNA. However, magnesium also promotes removal of the primer by the proof-reading 3′-5′ exonuclease activity. This problem is circumvented by including the carbonyldiphosphonate, which is a competitive inhibitor of polymerase activity (a pol III lacking the exonuclease activity may be used to avoid this particular problem).
  • A continuous flow of 60 μM carbonyldiphosphonate was maintained over the chip surface, to prevent the exonuclease activity from removing the primer from the target DNA.
  • Nucleotides Incorporating Two Blocking Groups
  • Each nucleotide (dCTP, dTTP, dGTP and dATP) contained a 1-(2-nitrophenyl)ethyl blocking group at the 5′ position, and a (4,5-dimethoxy-2-nitrobenzyl) oxycarbonyl blocking group at the 3′ position as shown in FIG. 3. The synthesis of the double blocked nucleotides was as follows:
  • Stage 1:—Synthesis of (4,5-dimethoxy-nitrobenzyl)oxycarbonyl-nucleoside triphosphate
  • The same overall method was applied to dGTP, dCTP and dTTP. A mixture of dATP dihydrate (0.4=01) and approximately 3 mmol of 4,5-dimethoxy-2-nitrophenyldiazomethane, freshly prepared from 900 mg (4 mmol) of 4,5-dimethoxy-2-nitrophenylhydrazone (synthesized by treatment of 6-nitroveraldehyde with hydrazine monohydrate in chloroform by the procedure of Wootton and Trentham, Photochemical Probes in Biochemistry (Nielsen, P. E., Ed,) NATO ASI Ser. C, Vol. 272, p277-296 (1989), was stirred in 15 ml of DMSO at room temperature in the dark for 40 h. Monitoring of the reaction by TLC in a chloroform/methanol (5:1 v/v) solvent system revealed the appearance of a spot with Rf 0.54 corresponding to the caged nucleotide. DMSO, unreacted diazo compound, and reaction products with low polarity were removed by repetitive extraction with 60 ml of ether. The residual material, which, among other substances, contained unreacted nucleotide and the desired product, was dissolved in a minimal amount of chloroform and separated by flash chromatography on a silica column (3×30 cm). Elution using 100% chloroform and methanol/chloroform (955 v/v) removed the hydrophobic side products of 4,5-dimethoxy-2-nitrophenyldiazomethane from the column. The fractions were dried on a rotary evaporator. 78 mg of the caged product was then lyophilised. The overall yield was 45%. The 3′ blocked 4,5-dimethyloxy-2-nitrobenzyl oxycarbonyl dATP was isolated directly with higher purity by preparative reverse-phased HPLC from the crude product.
  • Stage 2:—Addition of the 5′ 1-(2-nitrophenyl)ethyl group to the 3′ 4,5-dimethoxy-2-nitrobenzyl oxycarbonyl blocked dATP
  • A mixture of 4,5-dimethoxy-2-nitrobenzyl oxycarbonyl 5′ dATP (0.4 mmol) and approximately 3 mmol of 1-(2-nitrophenyl)diazoethane, freshly prepared from 716.7 mg (4 mmol) of hydrazone of 2-nitroacetophenone (synthesized by treatment of 2-nitroacetophenone with hydrazine monohydrate in ethanol) and 2.9 g (30 mmol) of MnO2 (90%) in 20 ml of chloroform by the procedure of walker et al (walker et al, Methods Enzymol. 1989; 172:288-301), was stirred in 15 ml of DMSO at room temperature in the dark for 40 h, Monitoring the reaction by TLC in a chloroform/methanol (5:1 v/v) solvent system revealed the appearance of a pair of spots with Rf 0.68 and Rf 0.58, corresponding to the two diasterioisomers of the axial and the two diasteroisomers of the equatorial form of the 1(2-nitrophenyl)ethyl ester of 4,5-dimethoxy-2-nitrobenzyl oxycarbonyl dATP, respectively. DMSO, unreacted diazo compound, and reaction products with low polarity were removed by repetitive extraction with 50 ml ether.
  • The residual material, which contained among other substances unreacted 4,5-dimethoxy-2-nitrobenzyl oxycarbonyl 5′ dATP and the desired double blocked dATP, was dissolved in a minimal amount of chloroform and separated by flash chromatography on a silica column 3×30 cm. Elution using 100% chloroform removed hydrophobic side products of 1-(2-nitrophenyl)diazoethane from the column. The product was dried on a rotary evaporator. Lyophilization gave 74 mg of the caged compound. The overall yield was 57%.
  • 0.2 mM of each nucleotide was present in the polymerisation buffer (1 mM Tris-HCl pH 8.8, 5 mM KCl, 0.15 mM MgCl2, 0.01% (w/v) gelatin).
  • DNA Sequencing
  • FIG. 1 shows a SPR sensing system and fluidic cell (7), having a means for applying electromagnetic radiation (1) to a sensor chip (2) with an immobilised polymerase enzyme (3) at the sensor surface, an inlet (4) for introducing the different nucleotides into the cell and two focusing assemblies (5) and (6) for pulsing monochromatic light into the cell.
  • The different nucleotides are introduced into the fluidic cell (7) at a flow rate of 30 μl/min., at a temperature of 25° C. and a data collection rate of 10 Hz. As the nucleotides pass the focusing assembly (5), monochromatic light at a wavelength of 260 nm is pulsed to remove the blocking group at the 5′ position. The nucleotides then flow over the sensor chip (2) and contact the target polynucleotide/polymerase complex (3) which is held in place by the β-dimer sub-assembly. Since the 3′ position on the primer sequence is free to react, polymerisation may take place as a nucleotide is incorporated onto its complement on the target polynucleotide. This incorporation is then detected by the monochromatic p-polarised light of the SPR device. No further polymerisation occurs, since the incorporated nucleotide has a blocking group at the 3′ position. Monochromatic light of wavelength 360 nm is then pulsed by the focusing assembly (6) at the site of polymerisation. The high flow rate in the fluidic cell ensures that nucleotides not bound to the polymerase are removed from the cell before sufficient energy has been absorbed to release their 3′ blocking groups.
  • Once the 3′ blocking group has been released from the polymerised nucleotide, further polymerisation may occur.
  • FIG. 2 shows the results from the sequencing experiment with each nucleotide incorporated into the nascent chain being detected. The results show a sequence complementary to that of SEQ ID No. 1.

Claims (21)

1. A method for sequencing a polynucleotide, comprising the steps of:
(i) reacting a target polynucleotide with a polymerase, wherein said polymerase is immobilized on a solid support, and nucleotides, under conditions sufficient for the polymerase reaction; and
(ii) detecting the interaction between the polymerase, the target polynucleotide, and each specific nucleotide complementary to the target polynucleotide that is incorporated into a nascent polynucleotide being synthesized as a result of the polymerase reaction, to thereby determine the sequence of the target polynucleotide, the detection being carried out by measuring a change in or absorption of radiation that occurs during the interaction.
2. The method according to claim 1, wherein steps (i) and (ii) are conducted with each of the complementary nucleotides in turn, until incorporation is detected, and then repeated.
3. The method according to claim 1, wherein step (i) is conducted with all the complementary nucleotides present.
4. The method according to claim 1, wherein the nucleotides comprise a 3′ blocking group which is removed after the polymerase reaction.
5. The method according to claim 4, wherein the blocking group is selectively removed by pulsed monochromatic light.
6. The method according to claim 4, wherein the nucleotides comprise a further blocking group at the terminal phosphate group of the triphosphate chain, and the further blocking group is removed prior to the removal of the 3′ blocking group.
7. The method according to claim 6, wherein the further blocking group is selectively removed by pulsed monochromatic light under conditions different from those required to remove the 3′ blocking group.
8. The method according to claim 7, wherein the further blocking group is removed by pulsing the monochromatic light for a duration different from that required to remove the 3′ blocking group.
9. The method according to claim 1, wherein step (i) further comprises introducing a competitive inhibitor of the polymerase.
10. The method according to claim 1, wherein the target polynucleotide of step (i) is bound to the polymerase enzyme by a β2 dimer complex.
11. The method according to claim 1, wherein the polymerase is E. coli DNA polymerase III or T7 polymerase.
12. The method according to claim 1, wherein the polymerase is a Taq polymerase.
13. The method according to claim 1, wherein the polymerase is reverse transcriptase.
14. The method according to claim 1, wherein step (ii) comprises detection of a change in resonance signal over time.
15. The method according to claim 1, wherein the radiation is electromagnetic.
16. The method according to claim 15, wherein the electromagnetic radiation is in the infra-red spectrum.
17. The method according to claim 1, wherein the incorporation of a nucleotide is detected using NMR.
18. The method according to claim 1, wherein the polynucleotide is DNA.
19. The method according to claim 1, wherein measurement is carried out using evanescent wave spectroscopy.
20. The method according to claim 1, wherein the nucleotides are not labeled.
21. The method according to claim 1, wherein the effect detected results from a conformation or mass change of the polymerase that occurs upon incorporation of the nucleotide.
US12/651,824 1997-07-28 2010-01-04 Nucleic Acid Sequence Analysis Abandoned US20100316999A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/651,824 US20100316999A1 (en) 1997-07-28 2010-01-04 Nucleic Acid Sequence Analysis

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB9715942.0A GB9715942D0 (en) 1997-07-28 1997-07-28
GB9715942.0 1997-07-28
GB9727103.5 1997-12-22
GBGB9727103.5A GB9727103D0 (en) 1997-12-22 1997-12-22
US09/463,549 US7008766B1 (en) 1997-07-28 1998-07-24 Nucleic acid sequence analysis
PCT/GB1998/002214 WO1999005315A2 (en) 1997-07-28 1998-07-24 Nucleic acid sequence analysis
US10/786,951 US20040241719A1 (en) 1997-07-28 2004-02-24 Nucleic acid sequence analysis
US11/833,673 US20080014592A1 (en) 1997-07-28 2007-08-03 Nucleic Acid Sequence Analysis
US12/651,824 US20100316999A1 (en) 1997-07-28 2010-01-04 Nucleic Acid Sequence Analysis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/833,673 Continuation US20080014592A1 (en) 1997-07-28 2007-08-03 Nucleic Acid Sequence Analysis

Publications (1)

Publication Number Publication Date
US20100316999A1 true US20100316999A1 (en) 2010-12-16

Family

ID=26311958

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/463,549 Expired - Lifetime US7008766B1 (en) 1997-07-28 1998-07-24 Nucleic acid sequence analysis
US10/786,951 Abandoned US20040241719A1 (en) 1997-07-28 2004-02-24 Nucleic acid sequence analysis
US11/833,673 Abandoned US20080014592A1 (en) 1997-07-28 2007-08-03 Nucleic Acid Sequence Analysis
US12/651,824 Abandoned US20100316999A1 (en) 1997-07-28 2010-01-04 Nucleic Acid Sequence Analysis

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US09/463,549 Expired - Lifetime US7008766B1 (en) 1997-07-28 1998-07-24 Nucleic acid sequence analysis
US10/786,951 Abandoned US20040241719A1 (en) 1997-07-28 2004-02-24 Nucleic acid sequence analysis
US11/833,673 Abandoned US20080014592A1 (en) 1997-07-28 2007-08-03 Nucleic Acid Sequence Analysis

Country Status (19)

Country Link
US (4) US7008766B1 (en)
EP (4) EP2267165B1 (en)
JP (1) JP2001511358A (en)
KR (1) KR100664331B1 (en)
CN (1) CN1152140C (en)
AT (1) ATE225858T1 (en)
AU (1) AU735898B2 (en)
BR (1) BR9812270A (en)
CA (1) CA2294962C (en)
DE (1) DE69808661T3 (en)
DK (1) DK1017848T3 (en)
ES (1) ES2183394T5 (en)
HK (1) HK1031130A1 (en)
IL (1) IL133411A (en)
IS (1) IS5360A (en)
NZ (1) NZ502557A (en)
PT (1) PT1017848E (en)
RU (1) RU2198221C2 (en)
WO (1) WO1999005315A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110097729A1 (en) * 2003-07-24 2011-04-28 Daniel Densham Apparatus and method for sequencing nucleic acid molecules
US9951385B1 (en) 2017-04-25 2018-04-24 Omniome, Inc. Methods and apparatus that increase sequencing-by-binding efficiency
US10077470B2 (en) 2015-07-21 2018-09-18 Omniome, Inc. Nucleic acid sequencing methods and systems
US10161003B2 (en) 2017-04-25 2018-12-25 Omniome, Inc. Methods and apparatus that increase sequencing-by-binding efficiency
US10246744B2 (en) 2016-08-15 2019-04-02 Omniome, Inc. Method and system for sequencing nucleic acids
US10294514B2 (en) 2016-04-29 2019-05-21 Omniome, Inc. Sequencing method employing ternary complex destabilization to identify cognate nucleotides
US10428378B2 (en) 2016-08-15 2019-10-01 Omniome, Inc. Sequencing method for rapid identification and processing of cognate nucleotide pairs
US10975427B2 (en) 2017-01-20 2021-04-13 Omniome, Inc. Process for cognate nucleotide detection in a nucleic acid sequencing workflow
US11193166B2 (en) 2017-10-19 2021-12-07 Omniome, Inc. Simultaneous background reduction and complex stabilization in binding assay workflows
US11248254B2 (en) 2016-12-30 2022-02-15 Omniome, Inc. Method and system employing distinguishable polymerases for detecting ternary complexes and identifying cognate nucleotides

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620209D0 (en) * 1996-09-27 1996-11-13 Cemu Bioteknik Ab Method of sequencing DNA
GB9626815D0 (en) 1996-12-23 1997-02-12 Cemu Bioteknik Ab Method of sequencing DNA
JP3935509B2 (en) * 1997-02-12 2007-06-27 ワイ. チャン,ユージーン Methods and products for polymer analysis
PT1017848E (en) * 1997-07-28 2003-02-28 Medical Biosystems Ltd ANALYSIS OF NUCLEIC ACID SEQUENCES
US7875440B2 (en) 1998-05-01 2011-01-25 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US6780591B2 (en) 1998-05-01 2004-08-24 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
US6232075B1 (en) 1998-12-14 2001-05-15 Li-Cor, Inc. Heterogeneous assay for pyrophosphate detection
JP2002537858A (en) * 1999-03-10 2002-11-12 エーエスエム サイエンティフィック, インコーポレイテッド Methods for direct sequencing of nucleic acids
AU2005201777B2 (en) * 1999-03-10 2007-08-02 Asm Scientific, Inc. A Method for Direct Nucleic Acid Sequencing
GB9907812D0 (en) * 1999-04-06 1999-06-02 Medical Biosystems Ltd Sequencing
GB9907813D0 (en) 1999-04-06 1999-06-02 Medical Biosystems Ltd Synthesis
EP1212338B1 (en) 1999-04-08 2012-11-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Nucleoside derivatives with photolabile protective groups
US7056661B2 (en) 1999-05-19 2006-06-06 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
EP1681356B1 (en) * 1999-05-19 2011-10-19 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
US6818395B1 (en) 1999-06-28 2004-11-16 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences
US7501245B2 (en) 1999-06-28 2009-03-10 Helicos Biosciences Corp. Methods and apparatuses for analyzing polynucleotide sequences
US6927065B2 (en) 1999-08-13 2005-08-09 U.S. Genomics, Inc. Methods and apparatus for characterization of single polymers
AU7086800A (en) * 1999-08-30 2001-03-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The High speed parallel molecular nucleic acid sequencing
US6982146B1 (en) 1999-08-30 2006-01-03 The United States Of America As Represented By The Department Of Health And Human Services High speed parallel molecular nucleic acid sequencing
GB9923644D0 (en) * 1999-10-06 1999-12-08 Medical Biosystems Ltd DNA sequencing
US6908736B1 (en) 1999-10-06 2005-06-21 Medical Biosystems, Ltd. DNA sequencing method
AU3163101A (en) * 1999-12-21 2001-07-03 Vbc-Genomics Bioscience Research Gmbh Compound comprising a nucleic acid moiety and an organo-silane moiety
GB0002389D0 (en) 2000-02-02 2000-03-22 Solexa Ltd Molecular arrays
GB0016473D0 (en) * 2000-07-05 2000-08-23 Amersham Pharm Biotech Uk Ltd Sequencing method
AU8288101A (en) 2000-07-07 2002-01-21 Visigen Biotechnologies Inc Real-time sequence determination
JP2004510433A (en) 2000-10-06 2004-04-08 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Massively parallel methods for decoding DNA and RNA
US9708358B2 (en) 2000-10-06 2017-07-18 The Trustees Of Columbia University In The City Of New York Massive parallel method for decoding DNA and RNA
WO2002044425A2 (en) 2000-12-01 2002-06-06 Visigen Biotechnologies, Inc. Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity
JP2004524525A (en) * 2001-01-30 2004-08-12 ソレックサ リミテッド Preparation of polynucleotide array
GB0112238D0 (en) * 2001-05-18 2001-07-11 Medical Biosystems Ltd Sequencing method
US7118907B2 (en) 2001-06-06 2006-10-10 Li-Cor, Inc. Single molecule detection systems and methods
US6613523B2 (en) 2001-06-29 2003-09-02 Agilent Technologies, Inc. Method of DNA sequencing using cleavable tags
US7668697B2 (en) * 2006-02-06 2010-02-23 Andrei Volkov Method for analyzing dynamic detectable events at the single molecule level
US6852492B2 (en) * 2001-09-24 2005-02-08 Intel Corporation Nucleic acid sequencing by raman monitoring of uptake of precursors during molecular replication
US6956114B2 (en) 2001-10-30 2005-10-18 '454 Corporation Sulfurylase-luciferase fusion proteins and thermostable sulfurylase
US6902921B2 (en) 2001-10-30 2005-06-07 454 Corporation Sulfurylase-luciferase fusion proteins and thermostable sulfurylase
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
GB0129012D0 (en) 2001-12-04 2002-01-23 Solexa Ltd Labelled nucleotides
DK3587433T3 (en) 2002-08-23 2020-05-18 Illumina Cambridge Ltd MODIFIED NUCLEOTIDES
US11008359B2 (en) 2002-08-23 2021-05-18 Illumina Cambridge Limited Labelled nucleotides
US7414116B2 (en) 2002-08-23 2008-08-19 Illumina Cambridge Limited Labelled nucleotides
JP2004347621A (en) * 2003-04-24 2004-12-09 Dainippon Printing Co Ltd Transmission type screen
GB0316553D0 (en) * 2003-07-15 2003-08-20 Densham Daniel Method
JP2007529999A (en) * 2003-07-15 2007-11-01 デンシャム,ダニエル,ヘンリー Measurement of polynucleotide amplification reaction
US7169560B2 (en) 2003-11-12 2007-01-30 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
US7977048B2 (en) 2004-01-13 2011-07-12 Pathogenetix, Inc. Detection and quantification of analytes in solution using polymers
US7595160B2 (en) 2004-01-13 2009-09-29 U.S. Genomics, Inc. Analyte detection using barcoded polymers
ATE463584T1 (en) 2004-02-19 2010-04-15 Helicos Biosciences Corp METHOD FOR ANALYZING POLYNUCLEOTIDE SEQUENCES
ES2439696T3 (en) 2004-04-09 2014-01-24 Monsanto Technology Llc Compositions and procedures for controlling insect infestations in plants
GB0413082D0 (en) 2004-06-11 2004-07-14 Medical Biosystems Ltd Method
US7476503B2 (en) 2004-09-17 2009-01-13 Pacific Biosciences Of California, Inc. Apparatus and method for performing nucleic acid analysis
US7170050B2 (en) 2004-09-17 2007-01-30 Pacific Biosciences Of California, Inc. Apparatus and methods for optical analysis of molecules
US7274458B2 (en) 2005-03-07 2007-09-25 3M Innovative Properties Company Thermoplastic film having metallic nanoparticle coating
US7666494B2 (en) 2005-05-04 2010-02-23 3M Innovative Properties Company Microporous article having metallic nanoparticle coating
WO2007007519A1 (en) * 2005-07-07 2007-01-18 Sony Corporation Substance information acquisition method and substance information measurement device using evanescent light, and base arrangement decision method and device
WO2007011331A2 (en) 2005-07-14 2007-01-25 3M Innovative Properties Company Water-soluble polymeric substrate having metallic nanoparticle coating
US7805081B2 (en) * 2005-08-11 2010-09-28 Pacific Biosciences Of California, Inc. Methods and systems for monitoring multiple optical signals from a single source
GB0517097D0 (en) 2005-08-19 2005-09-28 Solexa Ltd Modified nucleosides and nucleotides and uses thereof
US7666593B2 (en) 2005-08-26 2010-02-23 Helicos Biosciences Corporation Single molecule sequencing of captured nucleic acids
HUE031692T2 (en) * 2005-09-16 2017-07-28 Monsanto Technology Llc Methods for genetic control of insect infestations in plants and compositions thereof
US7405281B2 (en) 2005-09-29 2008-07-29 Pacific Biosciences Of California, Inc. Fluorescent nucleotide analogs and uses therefor
US7763423B2 (en) 2005-09-30 2010-07-27 Pacific Biosciences Of California, Inc. Substrates having low density reactive groups for monitoring enzyme activity
US7998717B2 (en) 2005-12-02 2011-08-16 Pacific Biosciences Of California, Inc. Mitigation of photodamage in analytical reactions
WO2007070542A2 (en) 2005-12-12 2007-06-21 The Government Of The United States Of America As Represented By The Secretary Of The Deptartment Ofhealth And Human Services Nanoprobes for detection or modification of molecules
US8703734B2 (en) 2005-12-12 2014-04-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nanoprobes for detection or modification of molecules
US7995202B2 (en) * 2006-02-13 2011-08-09 Pacific Biosciences Of California, Inc. Methods and systems for simultaneous real-time monitoring of optical signals from multiple sources
US7692783B2 (en) * 2006-02-13 2010-04-06 Pacific Biosciences Of California Methods and systems for simultaneous real-time monitoring of optical signals from multiple sources
US7715001B2 (en) 2006-02-13 2010-05-11 Pacific Biosciences Of California, Inc. Methods and systems for simultaneous real-time monitoring of optical signals from multiple sources
US8975216B2 (en) 2006-03-30 2015-03-10 Pacific Biosciences Of California Articles having localized molecules disposed thereon and methods of producing same
US7563574B2 (en) 2006-03-31 2009-07-21 Pacific Biosciences Of California, Inc. Methods, systems and compositions for monitoring enzyme activity and applications thereof
AU2007289057C1 (en) 2006-09-01 2014-01-16 Pacific Biosciences Of California, Inc. Substrates, systems and methods for analyzing materials
US8207509B2 (en) 2006-09-01 2012-06-26 Pacific Biosciences Of California, Inc. Substrates, systems and methods for analyzing materials
US20080076123A1 (en) * 2006-09-27 2008-03-27 Helicos Biosciences Corporation Polymerase variants for DNA sequencing
WO2008042067A2 (en) 2006-09-28 2008-04-10 Illumina, Inc. Compositions and methods for nucleotide sequencing
US20080080059A1 (en) * 2006-09-28 2008-04-03 Pacific Biosciences Of California, Inc. Modular optical components and systems incorporating same
GB2457402B (en) 2006-12-01 2011-10-19 Univ Columbia Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators
US8551704B2 (en) 2007-02-16 2013-10-08 Pacific Biosciences Of California, Inc. Controllable strand scission of mini circle DNA
US20080277595A1 (en) * 2007-05-10 2008-11-13 Pacific Biosciences Of California, Inc. Highly multiplexed confocal detection systems and methods of using same
US20100167413A1 (en) * 2007-05-10 2010-07-01 Paul Lundquist Methods and systems for analyzing fluorescent materials with reduced autofluorescence
DE102007022915A1 (en) * 2007-05-14 2008-11-20 Stiftung Caesar Center Of Advanced European Studies And Research Method for analyzing polymerization of analyte in fluid, particularly organic monomer, involves overflowing reaction medium before beginning of analyzing sensor surface
WO2009017678A2 (en) 2007-07-26 2009-02-05 Pacific Biosciences Of California, Inc. Molecular redundant sequencing
CA2700838A1 (en) 2007-09-28 2009-04-09 Pacific Biosciences Of California, Inc. Error-free amplification of dna for clonal sequencing
US7960116B2 (en) 2007-09-28 2011-06-14 Pacific Biosciences Of California, Inc. Nucleic acid sequencing methods and systems
EP2209911B1 (en) 2007-10-19 2013-10-16 The Trustees of Columbia University in the City of New York Dna sequencing with non-fluorescent nucleotide reversible terminators and cleavable label modified nucleotide terminators and a deoxyinosine analogue with a reversible terminator group
US20110014611A1 (en) 2007-10-19 2011-01-20 Jingyue Ju Design and synthesis of cleavable fluorescent nucleotides as reversible terminators for dna sequences by synthesis
US8802424B2 (en) 2008-01-10 2014-08-12 Pacific Biosciences Of California, Inc. Methods and systems for analysis of fluorescent reactions with modulated excitation
WO2009102470A2 (en) 2008-02-12 2009-08-20 Pacific Biosciences Of California, Inc. Compositions and methods for use in analytical reactions
US8143030B2 (en) 2008-09-24 2012-03-27 Pacific Biosciences Of California, Inc. Intermittent detection during analytical reactions
JP2011515102A (en) 2008-03-28 2011-05-19 パシフィック バイオサイエンシーズ オブ カリフォルニア, インコーポレイテッド Compositions and methods for nucleic acid sequencing
WO2009120374A2 (en) 2008-03-28 2009-10-01 Pacific Biosciences Of California, Inc. Methods and compositions for nucleic acid sample preparation
US8628940B2 (en) 2008-09-24 2014-01-14 Pacific Biosciences Of California, Inc. Intermittent detection during analytical reactions
US8198023B2 (en) 2008-08-05 2012-06-12 Pacific Biosciences Of California, Inc. Prevention and alleviation of steric hindrance during single molecule nucleic acid synthesis by a polymerase
WO2010027497A2 (en) 2008-09-05 2010-03-11 Pacific Biosciences Of California, Inc Preparations, compositions, and methods for nucleic acid sequencing
CA3063032A1 (en) 2008-09-16 2010-03-25 Pacific Biosciences Of California, Inc. Substrates and optical systems and methods of use thereof
US8481264B2 (en) 2008-09-19 2013-07-09 Pacific Biosciences Of California, Inc. Immobilized nucleic acid complexes for sequence analysis
US8921046B2 (en) 2008-09-19 2014-12-30 Pacific Biosciences Of California, Inc. Nucleic acid sequence analysis
US8383369B2 (en) 2008-09-24 2013-02-26 Pacific Biosciences Of California, Inc. Intermittent detection during analytical reactions
US8252910B2 (en) 2008-11-19 2012-08-28 Pacific Biosciences Of California, Inc. Modular nucleotide compositions and uses therefor
US8370079B2 (en) 2008-11-20 2013-02-05 Pacific Biosciences Of California, Inc. Algorithms for sequence determination
US8993230B2 (en) 2008-12-04 2015-03-31 Pacific Biosciences of Californ, Inc. Asynchronous sequencing of biological polymers
US9175338B2 (en) 2008-12-11 2015-11-03 Pacific Biosciences Of California, Inc. Methods for identifying nucleic acid modifications
WO2010068289A2 (en) 2008-12-11 2010-06-17 Pacific Biosciences Of California, Inc. Classification of nucleic acid templates
US20230148447A9 (en) 2008-12-11 2023-05-11 Pacific Biosciences Of California, Inc. Classification of nucleic acid templates
US8501405B2 (en) 2009-04-27 2013-08-06 Pacific Biosciences Of California, Inc. Real-time sequencing methods and systems
US8501406B1 (en) 2009-07-14 2013-08-06 Pacific Biosciences Of California, Inc. Selectively functionalized arrays
US8518643B2 (en) 2010-02-04 2013-08-27 Pacific Biosciences Of California, Inc. Method to improve single molecule analyses
CA2790393C (en) 2010-02-19 2019-03-12 Pacific Biosciences Of California, Inc. Integrated analytical system and method
WO2011116120A2 (en) * 2010-03-16 2011-09-22 Life Technologies Corporation Method and apparatus for addressable flow cells in single molecule sequencing
US8318094B1 (en) 2010-06-18 2012-11-27 Pacific Biosciences Of California, Inc. Substrate analysis systems
US8834847B2 (en) 2010-08-12 2014-09-16 Pacific Biosciences Of California, Inc. Photodamage mitigation compounds and systems
US8465922B2 (en) 2010-08-26 2013-06-18 Pacific Biosciences Of California, Inc. Methods and systems for monitoring reactions
EP2689028B1 (en) 2011-03-23 2017-08-30 Pacific Biosciences Of California, Inc. Isolation of polymerase-nucleic acid complexes and loading onto substrates
WO2012138973A2 (en) 2011-04-06 2012-10-11 The University Of Chicago COMPOSITION AND METHODS RELATED TO MODIFICATION OF 5-METHYLCYTOSINE (5mC)
WO2013019759A1 (en) * 2011-07-30 2013-02-07 The Regents Of The University Of California Enzymatic preparation of 10 base to 50 kb double-strand dna reagent for sequencing with a nanopore-polymerase sequencing device
WO2013056241A2 (en) 2011-10-14 2013-04-18 Pacific Biosciences Of California, Inc. Real-time redox sequencing
US9267917B2 (en) 2011-11-04 2016-02-23 Pacific Biosciences Of California, Inc. Nanopores in zero mode waveguides
US9238836B2 (en) 2012-03-30 2016-01-19 Pacific Biosciences Of California, Inc. Methods and compositions for sequencing modified nucleic acids
US9175348B2 (en) 2012-04-24 2015-11-03 Pacific Biosciences Of California, Inc. Identification of 5-methyl-C in nucleic acid templates
EP3388442A1 (en) 2013-03-15 2018-10-17 Illumina Cambridge Limited Modified nucleosides or nucleotides
US9416414B2 (en) 2013-10-24 2016-08-16 Pacific Biosciences Of California, Inc. Delaying real-time sequencing
US10302972B2 (en) 2015-01-23 2019-05-28 Pacific Biosciences Of California, Inc. Waveguide transmission
US10731211B2 (en) 2015-11-18 2020-08-04 Pacific Biosciences Of California, Inc. Methods and compositions for loading of polymerase complexes
US9932631B1 (en) 2017-09-11 2018-04-03 Omniome, Inc. Genotyping by polymerase binding
SG11201906567YA (en) 2017-01-20 2019-08-27 Omniome Inc Allele-specific capture of nucleic acids
US11078534B2 (en) * 2017-11-27 2021-08-03 Roche Molecular Systems, Inc. Photocleavable nucleotide reagents with high stability
SG11202012396QA (en) 2018-12-21 2021-01-28 Illumina Inc Sensing systems
TW202235626A (en) * 2020-11-16 2022-09-16 美商伊路米納有限公司 Incorporation and imaging mixes

Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3728032A (en) * 1971-10-13 1973-04-17 H Noll Flow cell for spectroscopic analysis of density gradients
GB2102005A (en) * 1981-07-23 1983-01-26 Mta Koezponti Kemiai Kutato In Process for synthesis of polydeoxynucleotides
US4863849A (en) * 1985-07-18 1989-09-05 New York Medical College Automatable process for sequencing nucleotide
US4971903A (en) * 1988-03-25 1990-11-20 Edward Hyman Pyrophosphate-based method and apparatus for sequencing nucleic acids
US5064754A (en) * 1984-12-14 1991-11-12 Mills Randell L Genomic sequencing method
US5087338A (en) * 1988-11-15 1992-02-11 Aligena Ag Process and device for separating electrically charged macromolecular compounds by forced-flow membrane electrophoresis
US5198766A (en) * 1991-02-11 1993-03-30 Bruker Analytische Messtechnik Gmbh Apparatus for measuring chemical and/or physical reaction sequences by nuclear magnetic resonance spectrometry
WO1993006241A1 (en) * 1991-09-16 1993-04-01 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Gene probe biosensor method
US5302509A (en) * 1989-08-14 1994-04-12 Beckman Instruments, Inc. Method for sequencing polynucleotides
US5360714A (en) * 1992-08-28 1994-11-01 Fox Chase Cancer Center Hepadnavirus polymerase gene product having RNA-dependent DNA priming and reverse transcriptase activities and methods of measuring the activities thereof
US5485277A (en) * 1994-07-26 1996-01-16 Physical Optics Corporation Surface plasmon resonance sensor and methods for the utilization thereof
US5620854A (en) * 1993-08-25 1997-04-15 Regents Of The University Of California Method for identifying biochemical and chemical reactions and micromechanical processes using nanomechanical and electronic signal identification
US5635608A (en) * 1994-11-08 1997-06-03 Molecular Probes, Inc. α-carboxy caged compounds
US5753439A (en) * 1995-05-19 1998-05-19 Trustees Of Boston University Nucleic acid detection methods
US5801042A (en) * 1994-08-18 1998-09-01 The Trustees Of Columbia University In The City Of New York Unique associated Kaposi's sarcoma virus sequences and uses thereof
US6159687A (en) * 1997-03-18 2000-12-12 Novo Nordisk A/S Methods for generating recombined polynucleotides
US6221642B1 (en) * 1994-08-31 2001-04-24 Cornell Research Foundation, Inc. Process for reconstituting the polymerase III* and other subassemblies of E. coli DNA polymerase III holoenzyme from peptide subunits
US6331392B1 (en) * 1997-03-05 2001-12-18 Anadys Pharmaceutical, Inc. Screen employing fluorescence anisotropy to identify compounds with affinity for nucleic acids
US6623929B1 (en) * 1999-04-06 2003-09-23 Medical Biosystems, Ltd. Polynucleotide synthesis using a processing enzyme
US6780591B2 (en) * 1998-05-01 2004-08-24 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US20040241719A1 (en) * 1997-07-28 2004-12-02 Densham Daniel Henry Nucleic acid sequence analysis
US20040241678A1 (en) * 2001-05-18 2004-12-02 Densham Daniel Henry Polynucleotide sequencing method
US6908736B1 (en) * 1999-10-06 2005-06-21 Medical Biosystems, Ltd. DNA sequencing method
US20050214849A1 (en) * 1999-10-06 2005-09-29 Densham Daniel H DNA sequencing method
US7033764B2 (en) * 1999-05-19 2006-04-25 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
US7604963B2 (en) * 2003-07-24 2009-10-20 Medical Biosystems Ltd Method for sequencing nucleic acid molecules
US7608397B2 (en) * 2004-06-11 2009-10-27 Medical Biosystems Ltd Method for determining biophysical properties
US7875440B2 (en) * 1998-05-01 2011-01-25 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US20140373606A1 (en) * 2012-02-03 2014-12-25 Agilent Technologies, Inc. Micromachined flow cell with freestanding fluidic tube

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001069A1 (en) 1988-07-20 1990-02-08 Segev Diagnostics, Inc. Process for amplifying and detecting nucleic acid sequences
SE462454B (en) 1988-11-10 1990-06-25 Pharmacia Ab METHOD FOR USE IN BIOSENSORS
GB8910880D0 (en) 1989-05-11 1989-06-28 Amersham Int Plc Sequencing method
WO1991006678A1 (en) * 1989-10-26 1991-05-16 Sri International Dna sequencing
DE69133293T2 (en) 1990-12-06 2004-05-27 Affymetrix, Inc., Santa Clara Processes and reagents for immobilized polymer synthesis on a very large scale
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
GB9208733D0 (en) 1992-04-22 1992-06-10 Medical Res Council Dna sequencing method
SE9201984D0 (en) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab IMPROVEMENT IN OPTICAL ASSAYS
AU5449094A (en) * 1992-11-02 1994-05-24 Affymax Technologies N.V. Novel photoreactive protecting groups
DE69430909T2 (en) 1993-03-19 2003-02-27 Sequenom Inc DNA SEQUENCE DETERMINATION BY MASS SPECTROMETRY ON THE WAY OF DEGRADATION WITH EXONUCLEASE
US5959098A (en) 1996-04-17 1999-09-28 Affymetrix, Inc. Substrate preparation process
US6331692B1 (en) * 1996-10-12 2001-12-18 Volker Krause Diode laser, laser optics, device for laser treatment of a workpiece, process for a laser treatment of workpiece

Patent Citations (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3728032A (en) * 1971-10-13 1973-04-17 H Noll Flow cell for spectroscopic analysis of density gradients
GB2102005A (en) * 1981-07-23 1983-01-26 Mta Koezponti Kemiai Kutato In Process for synthesis of polydeoxynucleotides
US5064754A (en) * 1984-12-14 1991-11-12 Mills Randell L Genomic sequencing method
US4863849A (en) * 1985-07-18 1989-09-05 New York Medical College Automatable process for sequencing nucleotide
US4971903A (en) * 1988-03-25 1990-11-20 Edward Hyman Pyrophosphate-based method and apparatus for sequencing nucleic acids
US5087338A (en) * 1988-11-15 1992-02-11 Aligena Ag Process and device for separating electrically charged macromolecular compounds by forced-flow membrane electrophoresis
US5302509A (en) * 1989-08-14 1994-04-12 Beckman Instruments, Inc. Method for sequencing polynucleotides
US5198766A (en) * 1991-02-11 1993-03-30 Bruker Analytische Messtechnik Gmbh Apparatus for measuring chemical and/or physical reaction sequences by nuclear magnetic resonance spectrometry
WO1993006241A1 (en) * 1991-09-16 1993-04-01 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Gene probe biosensor method
US5360714A (en) * 1992-08-28 1994-11-01 Fox Chase Cancer Center Hepadnavirus polymerase gene product having RNA-dependent DNA priming and reverse transcriptase activities and methods of measuring the activities thereof
US5620854A (en) * 1993-08-25 1997-04-15 Regents Of The University Of California Method for identifying biochemical and chemical reactions and micromechanical processes using nanomechanical and electronic signal identification
US5485277A (en) * 1994-07-26 1996-01-16 Physical Optics Corporation Surface plasmon resonance sensor and methods for the utilization thereof
US5801042A (en) * 1994-08-18 1998-09-01 The Trustees Of Columbia University In The City Of New York Unique associated Kaposi's sarcoma virus sequences and uses thereof
US6221642B1 (en) * 1994-08-31 2001-04-24 Cornell Research Foundation, Inc. Process for reconstituting the polymerase III* and other subassemblies of E. coli DNA polymerase III holoenzyme from peptide subunits
US5635608A (en) * 1994-11-08 1997-06-03 Molecular Probes, Inc. α-carboxy caged compounds
US5753439A (en) * 1995-05-19 1998-05-19 Trustees Of Boston University Nucleic acid detection methods
US6331392B1 (en) * 1997-03-05 2001-12-18 Anadys Pharmaceutical, Inc. Screen employing fluorescence anisotropy to identify compounds with affinity for nucleic acids
US6159687A (en) * 1997-03-18 2000-12-12 Novo Nordisk A/S Methods for generating recombined polynucleotides
US7008766B1 (en) * 1997-07-28 2006-03-07 Medical Biosystems, Ltd. Nucleic acid sequence analysis
US20080014592A1 (en) * 1997-07-28 2008-01-17 Densham Daniel H Nucleic Acid Sequence Analysis
US20040241719A1 (en) * 1997-07-28 2004-12-02 Densham Daniel Henry Nucleic acid sequence analysis
US20110183323A1 (en) * 1998-05-01 2011-07-28 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and dna molecules
US20110183321A1 (en) * 1998-05-01 2011-07-28 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and dna molecules
US20110183322A1 (en) * 1998-05-01 2011-07-28 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and dna molecules
US7875440B2 (en) * 1998-05-01 2011-01-25 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US7645596B2 (en) * 1998-05-01 2010-01-12 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US6780591B2 (en) * 1998-05-01 2004-08-24 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US6623929B1 (en) * 1999-04-06 2003-09-23 Medical Biosystems, Ltd. Polynucleotide synthesis using a processing enzyme
US7485424B2 (en) * 1999-05-19 2009-02-03 Cornell Research Foundation, Inc. Labeled nucleotide phosphate (NP) probes
US20110111401A1 (en) * 1999-05-19 2011-05-12 Cornell University Method for sequencing nucleic acid molecules
US7361466B2 (en) * 1999-05-19 2008-04-22 Cornell Research Foundation, Inc. Nucleic acid analysis using terminal-phosphate-labeled nucleotides
US7416844B2 (en) * 1999-05-19 2008-08-26 Cornell Research Foundation, Inc. Composition for nucleic acid sequencing
US7943305B2 (en) * 1999-05-19 2011-05-17 Cornell Research Foundation High speed nucleic acid sequencing
US7056676B2 (en) * 1999-05-19 2006-06-06 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
US7056661B2 (en) * 1999-05-19 2006-06-06 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
US7943307B2 (en) * 1999-05-19 2011-05-17 Cornell Research Foundation Methods for analyzing nucleic acid sequences
US7052847B2 (en) * 1999-05-19 2006-05-30 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
US7033764B2 (en) * 1999-05-19 2006-04-25 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
US20110177520A1 (en) * 1999-10-06 2011-07-21 Daniel Henry Densham Dna sequencing method
US20050214849A1 (en) * 1999-10-06 2005-09-29 Densham Daniel H DNA sequencing method
US7939264B1 (en) * 1999-10-06 2011-05-10 Gen-Probe Incorporated DNA sequencing method
US6908736B1 (en) * 1999-10-06 2005-06-21 Medical Biosystems, Ltd. DNA sequencing method
US20090029383A1 (en) * 2001-05-18 2009-01-29 Daniel Henry Densham Polynucleotide Sequencing Method
US20040241678A1 (en) * 2001-05-18 2004-12-02 Densham Daniel Henry Polynucleotide sequencing method
US7604963B2 (en) * 2003-07-24 2009-10-20 Medical Biosystems Ltd Method for sequencing nucleic acid molecules
US20110097729A1 (en) * 2003-07-24 2011-04-28 Daniel Densham Apparatus and method for sequencing nucleic acid molecules
US7888073B2 (en) * 2003-07-24 2011-02-15 Gen-Probe Incorporated Method for sequencing nucleic acid molecules
US7608397B2 (en) * 2004-06-11 2009-10-27 Medical Biosystems Ltd Method for determining biophysical properties
US20140373606A1 (en) * 2012-02-03 2014-12-25 Agilent Technologies, Inc. Micromachined flow cell with freestanding fluidic tube

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Fungi," (Wikipedia.com; accessed 03 June 2013). *
"How many species of bacteria are there" (wisegeek.com; accessed 21 January 2014). *
"List of sequenced bacterial genomes" (Wikipedia.com; accessed 24 January 2014). *
"Mammal," (Wikipedia.com; accessed 22 September 2011 ) *
"Mammal," (Wikipedia.com; accessed 22 September 2011) *
"Murinae," (Wikipedia.com, accessed 18 March 2013). *
"Plant," (Wikipedia.com; accessed 08 March 2013). *
"Viruses" (Wikipedia.com, accessed 24 November 2012). *
“List of sequenced bacterial genomes” (Wikipedia.com; accessed 24 January 2014). *
“Mammal,” (Wikipedia.com; accessed 22 September 2011). *
“Murinae,” (Wikipedia.com, accessed 18 March 2013). *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592183B2 (en) 2003-07-24 2013-11-26 Gen-Probe Incorporated Apparatus and method for sequencing nucleic acid molecules
US20110097729A1 (en) * 2003-07-24 2011-04-28 Daniel Densham Apparatus and method for sequencing nucleic acid molecules
US11499185B2 (en) 2015-07-21 2022-11-15 Pacific Biosciences Of California, Inc. Nucleic acid sequencing methods and systems
US10077470B2 (en) 2015-07-21 2018-09-18 Omniome, Inc. Nucleic acid sequencing methods and systems
US10633692B2 (en) 2016-04-29 2020-04-28 Omniome, Inc. Sequencing method employing ternary complex destabilization to identify cognate nucleotides
US11203778B2 (en) 2016-04-29 2021-12-21 Omniome, Inc. Sequencing method employing ternary complex destabilization to identify cognate nucleotides
US10294514B2 (en) 2016-04-29 2019-05-21 Omniome, Inc. Sequencing method employing ternary complex destabilization to identify cognate nucleotides
US11168364B2 (en) 2016-08-15 2021-11-09 Omniome, Inc. Method and system for sequencing nucleic acids
US10443098B2 (en) 2016-08-15 2019-10-15 Omniome, Inc. Method and system for sequencing nucleic acids
US10428378B2 (en) 2016-08-15 2019-10-01 Omniome, Inc. Sequencing method for rapid identification and processing of cognate nucleotide pairs
US10246744B2 (en) 2016-08-15 2019-04-02 Omniome, Inc. Method and system for sequencing nucleic acids
US11203779B2 (en) 2016-08-15 2021-12-21 Omnionie, Inc. Sequencing method for rapid identification and processing of cognate nucleotide pairs
US11248254B2 (en) 2016-12-30 2022-02-15 Omniome, Inc. Method and system employing distinguishable polymerases for detecting ternary complexes and identifying cognate nucleotides
US10975427B2 (en) 2017-01-20 2021-04-13 Omniome, Inc. Process for cognate nucleotide detection in a nucleic acid sequencing workflow
US10655176B2 (en) 2017-04-25 2020-05-19 Omniome, Inc. Methods and apparatus that increase sequencing-by-binding efficiency
US10161003B2 (en) 2017-04-25 2018-12-25 Omniome, Inc. Methods and apparatus that increase sequencing-by-binding efficiency
US11447823B2 (en) 2017-04-25 2022-09-20 Pacific Biosciences Of California, Inc. Methods and apparatus that increase sequencing-by-binding efficiency
US9951385B1 (en) 2017-04-25 2018-04-24 Omniome, Inc. Methods and apparatus that increase sequencing-by-binding efficiency
US11193166B2 (en) 2017-10-19 2021-12-07 Omniome, Inc. Simultaneous background reduction and complex stabilization in binding assay workflows

Also Published As

Publication number Publication date
NZ502557A (en) 2002-02-01
PT1017848E (en) 2003-02-28
US20080014592A1 (en) 2008-01-17
CN1152140C (en) 2004-06-02
EP1229133B1 (en) 2016-03-09
EP1017848B2 (en) 2012-02-22
DK1017848T3 (en) 2003-02-10
WO1999005315A3 (en) 1999-04-22
AU735898B2 (en) 2001-07-19
EP2267165A2 (en) 2010-12-29
IS5360A (en) 2000-01-25
EP1017848A2 (en) 2000-07-12
HK1031130A1 (en) 2001-06-01
ES2183394T5 (en) 2012-05-03
ES2183394T3 (en) 2003-03-16
CN1265158A (en) 2000-08-30
RU2198221C2 (en) 2003-02-10
WO1999005315A2 (en) 1999-02-04
JP2001511358A (en) 2001-08-14
EP1229133A3 (en) 2004-10-13
DE69808661T3 (en) 2012-05-03
EP2267164B1 (en) 2016-09-14
EP2267164A2 (en) 2010-12-29
IL133411A (en) 2003-09-17
KR20010022392A (en) 2001-03-15
KR100664331B1 (en) 2007-01-02
EP1229133A2 (en) 2002-08-07
US20040241719A1 (en) 2004-12-02
EP2267165A3 (en) 2012-10-10
EP1017848B1 (en) 2002-10-09
CA2294962A1 (en) 1999-02-04
ATE225858T1 (en) 2002-10-15
CA2294962C (en) 2012-09-18
EP2267165B1 (en) 2016-11-30
AU8455998A (en) 1999-02-16
IL133411A0 (en) 2001-04-30
EP2267164A3 (en) 2012-08-15
BR9812270A (en) 2000-07-18
DE69808661D1 (en) 2002-11-14
DE69808661T2 (en) 2003-07-31
US7008766B1 (en) 2006-03-07

Similar Documents

Publication Publication Date Title
US7008766B1 (en) Nucleic acid sequence analysis
CA2386115C (en) Dna sequencing method
US6908736B1 (en) DNA sequencing method
US20080096206A1 (en) Polynucleotide Sequencing Using a Helicase
EP1182267B1 (en) Method of determining base sequence of single nucleic acid molecule
AU751766B2 (en) Nucleic acid sequence analysis
CA2598670A1 (en) Dna crosslinking for primer extension assays
MXPA00000715A (en) Nucleic acid sequence analysis

Legal Events

Date Code Title Description
AS Assignment

Owner name: MOBIOUS BIOSYSTEMS LIMITED, UNITED KINGDOM

Free format text: CHANGE OF NAME;ASSIGNOR:REJUVIGEN LIMITED;REEL/FRAME:024896/0336

Effective date: 20070323

Owner name: GEN-PROBE INCORPORATED, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MOBIOUS BIO SYSTEMS LIMITED;REEL/FRAME:024896/0309

Effective date: 20091117

Owner name: REJUVIGEN LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDICAL BIOSYSTEMS LIMITED;REEL/FRAME:024896/0283

Effective date: 20070724

AS Assignment

Owner name: GOLDMAN SACHS BANK USA, NEW YORK

Free format text: SECURITY AGREEMENT;ASSIGNORS:HOLOGIC, INC.;BIOLUCENT, LLC;CYTYC CORPORATION;AND OTHERS;REEL/FRAME:028810/0745

Effective date: 20120801

AS Assignment

Owner name: CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP, MASSACHUSETTS

Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239

Effective date: 20150529

Owner name: CYTYC CORPORATION, MASSACHUSETTS

Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239

Effective date: 20150529

Owner name: BIOLUCENT, LLC, MASSACHUSETTS

Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239

Effective date: 20150529

Owner name: CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP, MASS

Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239

Effective date: 20150529

Owner name: SUROS SURGICAL SYSTEMS, INC., MASSACHUSETTS

Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239

Effective date: 20150529

Owner name: THIRD WAVE TECHNOLOGIES, INC., MASSACHUSETTS

Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239

Effective date: 20150529

Owner name: HOLOGIC, INC., MASSACHUSETTS

Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239

Effective date: 20150529

Owner name: GEN-PROBE INCORPORATED, MASSACHUSETTS

Free format text: SECURITY INTEREST RELEASE REEL/FRAME 028810/0745;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:035820/0239

Effective date: 20150529

AS Assignment

Owner name: BANK OF AMERICA, N.A., AS COLLATERAL AGENT, NORTH CAROLINA

Free format text: SECURITY AGREEMENT;ASSIGNORS:HOLOGIC, INC.;BIOLUCENT, LLC;CYTYC CORPORATION;AND OTHERS;REEL/FRAME:036307/0199

Effective date: 20150529

Owner name: BANK OF AMERICA, N.A., AS COLLATERAL AGENT, NORTH

Free format text: SECURITY AGREEMENT;ASSIGNORS:HOLOGIC, INC.;BIOLUCENT, LLC;CYTYC CORPORATION;AND OTHERS;REEL/FRAME:036307/0199

Effective date: 20150529

AS Assignment

Owner name: CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP, MASSACHUSETTS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529

Effective date: 20150529

Owner name: GOLDMAN SACHS BANK USA, NEW YORK

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT;ASSIGNORS:HOLOGIC, INC.;BIOLUCENT, LLC;CYTYC CORPORATION;AND OTHERS;REEL/FRAME:044432/0565

Effective date: 20120801

Owner name: BIOLUCENT, LLC, MASSACHUSETTS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529

Effective date: 20150529

Owner name: CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP, MASS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529

Effective date: 20150529

Owner name: GEN-PROBE INCORPORATED, MASSACHUSETTS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529

Effective date: 20150529

Owner name: HOLOGIC, INC., MASSACHUSETTS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529

Effective date: 20150529

Owner name: CYTYC CORPORATION, MASSACHUSETTS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529

Effective date: 20150529

Owner name: THIRD WAVE TECHNOLOGIES, INC., MASSACHUSETTS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529

Effective date: 20150529

Owner name: SUROS SURGICAL SYSTEMS, INC., MASSACHUSETTS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE;ASSIGNOR:GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT;REEL/FRAME:044727/0529

Effective date: 20150529

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE